News archive
Showing 765 results
September 2025
-
Story Discovery
What Are GTTs? These Technologies Can Impact How a Gene Functions
These scientifically advanced technologies may help transform millions of patients’ lives
-
Story Education and Awareness
A Breakthrough for Patients: 25 Year Anniversary of Innovation in Treating CML
Twenty-five years ago, Novartis pioneered a paradigm shift in cancer care with the introduction of the first tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML), transforming it from a deadly disease into a chronic condition for most patients. This breakthrough helped lay the foundation for targeted therapies in oncology and continues to shape the future of CML treatment today.
August 2025
-
Story Education and Awareness
Five Questions with Reshema Kemps-Polanco, Novartis US Chief Commercial Officer
In this interview, Reshema Kemps-Polanco shares her top career tips, the mindset that drives her, and the quote she still lives by today.
-
Story Discovery
Novartis in San Diego: A Quarter Century of R&D Innovation
A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site. -
Story Discovery
Designing for the Future: The Next Era of Biomedical Research in San Diego
Thierry Diagana, California Sites Head at Novartis, shares the vision for a new research hub that will power future drug discovery.
-
Media Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 … -
Media Release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's… -
Story Education and Awareness
Maurice’s Story: How I Discovered I Had a Hidden Heart Disease Risk Factor
Maurice W.*, a Medical Science Liaison at Novartis, was shocked to learn he had elevated Lp(a), an inherited risk factor for heart disease.1,2
July 2025
-
Media Release
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5… -
Story Education and Awareness
Tina’s Story: One Woman’s Burden of Living With Sjogren's Disease
-
Media Release
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety…
